Stock Update (NYSE:GE): Heritage Valley Health System and GE Healthcare Enter Multi-Year Strategic Relationship

[Business Wire] – Heritage Valley Health System today announced an innovative, strategic alliance with GE Healthcare aimed to propel the health system’s momentum of obtaining advanced medical equipment over the next 14 years. Read more on this. General Electric Company (GE) , currently valued at $276.38B, finished yesterday at $29.87. Today, shares have traded between $29.98 and $30.08 per share with a trailing 52-week range being $19.37 to $32.05. GE shares are currently priced at 19.78x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 16.50x earnings multiple for the same period. The company pays shareholders $0.92 per share in dividend income per year, for a current yield of 3.05%. Consensus earnings for the current quarter by the 12 sell-side analysts covering the stock is an estimate of $0.46 per share, which would be $0.15 better than the year-ago quarter and a $0.18 sequential increase. The full-year EPS estimate is $1.51 which would be a $0.20 improvement than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $30.69 Billion. If reported, that would be a 3.47% increase over the year-ago quarter. In terms of ratings, Bernstein downgraded GE from Outperform to Mkt Perform (Apr 4, 2016). Previously, UBS Initiated GE at to Buy. Investors should keep in mind is that the average price target is $33.23, which is 11.25% above where the stock opened this morning. See more in (NYSE:GE) Similar Articles: Market Update (NYSE:GE): Imbio and GE Healthcare Collaborate to Enable Lung Density Analysis™ Within GE Health Cloud Ecosystem Stock Update (NYSE:GE): LeukoDx and GE Healthcare Enter Agreement to Explore Solutions for Cell Characterization in Cell Therapy Manufacturing Company Update: General Electric Company (NYSE:GE) – 81% of Consumers are Unsatisfied with their Healthcare Experience, According to a New Study by Prophet and GE Healthcare Camden Group